Mangoceuticals, Inc. (NASDAQ:MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions and its partner IntraMont Technologies, Inc. today announced the filing of a Patent Cooperation Treaty (PCT) international application (P-641039-PC) on February 26, 2026, to secure broad global patent protection for the antiviral animal feed and drinking water additive technology that powers MGX-0024.

This PCT filing directly extends the intellectual property portfolio supporting the results highlighted in the February 23, 2026 press release, including zero respiratory-related mortality across 29,000 birds in commercial field trials and statistically significant prophylactic benefit against highly pathogenic H5N1 in the ICAR-NIHSAD controlled challenge study.

The application, titled "ANTIVIRAL ANIMAL FEED OR DRINKING WATER ADDITIVE AND METHODS FOR INHIBITING RESPIRATORY OR ORALLY ACQUIRED VIRUS INFECTION IN ANIMALS OR BIRDS THEREWITH," claims priority to U.S. Provisional Patent Application No. 63/763,785 filed February 26, 2025. It enables pursuit of patent protection in over 150 countries through a single streamlined process.

The technology remains protected in the U.S. under Patent No. 11,517,523, with corresponding national patents already granted or pending in the EU, Canada, China, India, Australia, and Japan.